In situ differentiation of adoptively transferred p21-engineered Mos into phagocytosis-proficient TAMs reduces the tumor burden and prolongs the survival of T-ALL-bearing NSG mice. The gene discussed is CDKN1A; the disease is acute lymphoblastic leukemia.